<DOC>
	<DOCNO>NCT00008112</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Hyperthermia therapy kill tumor cell heat several degree body temperature . Combining hyperthermia radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness cisplatin combine radiation therapy hyperthermia treat patient stage II , stage III , stage IV cervical cancer .</brief_summary>
	<brief_title>Cisplatin Combined With Radiation Therapy Hyperthermia Treating Patients With Stage II , Stage III , Stage IV Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility add cisplatin locoregional hyperthermia external beam intracavity radiotherapy patient stage IIB-IVA cervical cancer . - Determine acute toxicity regimen patient . - Determine complete response rate patient treat regimen . OUTLINE : This multicenter study . Patients undergo external beam radiotherapy ( EBRT ) daily 5 day week 5 week . On 1 day week , patient also receive cisplatin IV 3 hour hyperthermia 90 minute begin 1-6 hour completion EBRT . During week 6 , patient receive hyperthermia cisplatin day 1 day intracavity radiotherapy . Treatment continue absence unacceptable toxicity . Patients follow 6-8 week , every 3 month 3 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 6-34 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIBIVA carcinoma cervix Adenocarcinoma Squamous cell carcinoma Mixed cell histology No small cell anaplastic histology No paraaortic lymph node involvement No indication paraaortic radiotherapy No distant metastases No CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 7.0 mmol/L ( approximately 11 g/dL ) Epoetin alfa and/or transfusion allow Hepatic : Not specify Renal : Glomerular filtration rate least 60 mL/min Cardiovascular : No myocardial infarction within past 6 month No unstable angina No congestive heart failure expect inability tolerate fluid load No cerebrovascular accident within past 6 month Other : No pacemaker and/or metal implant No active uncontrolled infection No compromise immune status No psychosis No prior malignancy except nonmelanoma skin cancer No mental physical inability would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy Surgery : No prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>